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From the Editor’s Desk
Dear Readers
It gives me immense pleasure to present the first
issue of LABRAD in the post COVID 19 era. While
the threat of the pandemic is not entirely over, its
intensity has significantly abated globally. The
world has opened and is learning to adapt to the new
normal. As things begin to become normal around
the world, we all need to realize that the reason the
pandemic has been controlled so quickly and we
could enter the “post-pandemic era “is due to strict
application of scientific knowledge. It was only due
to the tremendous advancements in science and
technology that an effective vaccine was developed
in record time, which led to the rapid control of the
pandemic. The pandemic resulted in an extremely
high mortality and morbidity all over the world. We
need to salute the health care workers especially the
personnel working in clinical laboratory settings
around the world who worked throughout on the
front lines in combating the pandemic. Now that the
situation has returned to normal “and the dance of
death” which claimed hundreds and thousands of
lives around the world has practically ended, it felt

appropriate that we celebrate the miracle of life and
my team thought we could do this best by dedicating
this issue of LABRAD to the celebration of the
beginning of life. We decided that this issue should
be on mother and child diagnostics pertaining to
screening and diagnostic tests which are essential in
ensuring the safety and good health of the mother
and baby, not just before, but also after the baby is
born. Thus, we aim to provide the latest diagnostic
updates for the “beginning of life “. A compilation
of articles covering this topic are being presented
in this issue. These include some interesting writeups on TSH antibodies in pregnancy and newborns,
AADC deficiency, radiological screening for cranial
anomalies, red cell screening, maternal infections,
gestational trophoblastic tumors, and others.
I hope that you will find this issue interesting and
informative. My team will appreciate your valuable
opinion and feedback as well as constructive
suggestions to make future issues better, more
informative, and useful.
Dr Sidra Arshad
Editor, LabRad

LABRAD Star Contributors for the Year 2021
Ms. Nazneen Islam 					
Manager Molecular Pathology		

Ms. Iffat Arman

Warmest congratulations to Ms. Nazneen Islam and
Ms. Iffat Arman on your hard work and outstanding
contributions to the LABRAD. This demands time
and energy, and we deeply appreciate your efforts

to make it an immense success. Also, we encourage
everyone to contribute more to the issues to become
star contributors of the LABRAD for 2022.

Senior Technologist, Chemical Pathology
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Clinical Relevance of Measuring ThyroidStimulating Hormone Receptor Antibodies in
Pregnancy and Newborns
Mr Masab Azeem and Dr Hafsa Majid
Clinical Chemistry

Graves’ disease occurs before pregnancy in 0.4–1
percent of women and in 0.2–0.4 percent during
pregnancy, representing the most common cause (85
percent) of either overt or subclinical hyperthyroidism
in women of reproductive age. A more frequent and
peculiar form of hyperthyroidism in pregnancy is
the gestational transient thyrotoxicosis (GTT) whose
prevalence in the Asian population is 5.5–11 percent.
GTT is defined as transient thyrotoxicosis caused by
the stimulating effect β-HCG has on the TSH receptor
toward the end of the first trimester of gestation and
is frequently associated with hyperemesis gravidarum
and twin pregnancies.

The detection of TTRAbs is helpful in the
identification of the etiology of thyrotoxicosis and is a
hallmark for the diagnosis of Grave’s disease. TRAbs
can act on Thyroid Stimulating Hormone Receptor
(TSHR) to have a stimulating, blocking, or a neutral
effect.
During pregnancy the Thyroid antibodies can cross
the placental barrier and affect the fetal thyroid to
cause fetal hyperthyroidism. Untreated maternal
Grave’s disease can lead to fetal hyperthyroidism,
perinatal mortality, premature delivery, congestive
heart failure, craniosynostosis, microcephaly,
and psychomotor disabilities. After parturition,
newborn is tested for TRAB to evaluate for fetal
hyperthyroidism.
The drug of choice for overt hyperthyroidism in
pregnancy is Antithyroid drugs. Radioactive iodine is
contraindicated in pregnant women. Surgery is only
indicated when there are severe side effects of ATDs
or uncontrolled thyrotoxicosis. However, serum T3
and T4 must be monitored closely as the side effect
of these treatments is maternal hypothyroidism. The
sequalae of maternal hypothyroidism is two pronged:
maternal adverse effects include pre-eclampsia and
placental abruption, fetal adverse effects include
spontaneous abortion, preterm birth, low birth weight,
intrauterine growth restriction.
In Pakistan, the prevalence of overt and sub clinical
hyperthyroidism is reported to be 5.1 percent and
5.8 percent, respectively so for better maternal and
fetal outcome there is a need to monitor maternal and
neonatal Thyroid-Stimulating Hormone Receptor
Antibodies of high-risk pregnancies.

Figure 1: The stimulation of TSH receptor (TSHR) in pregnancy (Bucci
I et al.)

4

Reference:
Bucci, I., Giuliani, C., & Napolitano, G. (2017). Thyroid-Stimulating
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Frontiers in endocrinology, 8, 137.
https://doi.org/10.3389/fendo.2017.00137

JUNE 2022

VOL 47, ISSUE 1

Aromatic l-amino Acid Decarboxylase (AADC)
Deficiency- An Ultra-rare and Underdiagnosed
Neurometabolic Disorder
Iffat Arman and Dr Sibtain Ahmed
Clinical Chemistry

AADC deficiency is a very rare genetic disorder
characterized by decreased activity of aromatic
l-amino acid decarboxylase, an enzyme involved
in the building (synthesis) of neurotransmitters
(dopamine, serotonin, norepinephrine, and
epinephrine.), which are responsible for the
communication between neurons in the nervous
system. The first case was reported in 1990 and since
then approximately 135 patients have been reported
in global literature. The disorder is characterized
by, significant reduction or complete loss of AADC
enzyme activity, leading to severe combined
deficiency of serotonin, dopamine, norepinephrine,
and epinephrine due to mutations in the dopa
decarboxylase (DDC) gene. Signs and symptoms
onset usually occurs during first year of life as
depicted in Table 01.

and genetic testing for the confirmation of AADC
deficiency. Moreover, urine organic acid (UOA) is
Table 1: Signs and Symptoms of AADC Patients
a relatively simple and non-invasive test compared
to CSF
Sign in AADC
Symptoms in AADC
sampling
which is
Axial hypotonia
 Autonomic dysfunction/instability
technically
 Ptosis
 Limbhypertonia
challenging
 Excessive sweating
 Developmental Delay
as well.
 Nasal congestion
 Dystonia
The exact
 Arterial hypotension
 Hypokinesia
prevalence
 Temperature instability
 Bradykinesia
of AADC
 Mood instability
 Tremor
deficiency
 Irritability
 Athetosis
in
 Sleep disturbance
Pakistan is
 Myoclonic jerks
unknown,

Insomnia
and/or
hypersomnia
 Blepharospasm
however
 Changes in melatonin levels
 Oculogyric crises
the
 Feeding/swallowing problems.
availability
of UOA
From diagnostic perspective, urine organic acid
analysis at AKUH clinical laboratories emphasizes the
(UOA) analysis serves as a vital diagnostic modality
need for increased clinical awareness and empowered
with specifically elevated vanillactic acid and
diagnostic suspicion, intending to deliver better care
N-acetylvanilalanine. This first clue further guides
to Pakistani patients.
the way for other investigations including CSF
analysis for neurotransmitters, AADC enzyme activity
5
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Role of Flowcytometry & Kleihauer - Betke
Test in Detection and Quantification of
Fetomaternal Haemorrhage
Dr Maria Owais and Dr Anila Rashid
Haematology & Transfusion Medicine

Fetomaternal haemorrhage (FMH) despite being a
rare contributing cause of obstetric haemorrhage
with a global occurrence of three in 1000 live
births, is still a detrimental cause of intra-uterine
fetal demise and neonatal death. In RhD negative
females, calculating the size of FMH after events
such as delivery, abortion or any other invasive
procedures is a crucial step in determining
the proper dose of RhD immunoglobulin. The
Kleihauer Betke (KB) acid elution test, which
involves microscopic estimation of the fetal red
cells on a glass slide and exposing it to an acidic
pH solution, has long been used for detecting
and quantifying fetal red cells in the maternal
circulation. Because haemoglobin A is acid-soluble,
the maternal red blood cells become the “ghost”
cells whereas, the fetal red cells remain pink as
haemoglobin F is resistant to acid elution (Figure
1). However, KB test has several limitations which
includes, underestimation of FMH due to improper
staining, inadequate drying, short buffering time
and inter/intra-observer variation. Additionally,
ABO incompatibility and alloimmunization
shortens the lifespan of fetal red cells in maternal
circulation as well as the use of a pre-determined
maternal blood volume of five litres in the routine
calculations when determining the volume of an
overweight pregnant woman can be a cause of
FMH underestimation. False over-estimation can
result in underweight pregnant woman and during
advanced gestational age where fetal cells in the
maternal circulation are increased by seven percent.
Difference in FMH volume is also affected by
variation in the formulas used for the calculation.
Therefore, with such limitations posing concerns
over the detection and estimation of FMH volume,

6

the paradigm has shifted to alternative and more
accurate technique of flow cytometry which
is based on the use of monoclonal antibodies
against fetal red cells which are then quantified
by fluorescence intensity. Flowcytometry is
more accurate, reliable, reproducible, and less
labor intensive compared to KB test. Flow
cytometry can also detect large bleed more
accurately in comparison to the KB test, therefore,
allowing optimal administration of anti-D
immunoglobulins.
Both tests help in calculating the dosage of anti-D
immunoglobulin that needs to be administered to
RhD negative mother when the delivered baby is
RhD positive or after every potential sensitizing
event.

Figure 1: Dark pink fetal red cell (arrow) with background “ghost”
maternal red cells.
Source of Image: 2022 UpToDate, Inc. and/or its affiliates.
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Gestational Trophoblastic Diseases: An Overview
Dr Romana Idress, Dr Qurratulain Chundriger and
Dr Manahil Khan
Histopathology

Gestational trophoblastic disease (GTD) comprises
of a spectrum of disorders varying from hydatidiform
moles and gestational trophoblastic neoplasia (GTN).
GTN is further classified into hydatidiform mole
(HM), invasive mole, choriocarcinoma, placental
site trophoblastic tumor (PSTT), and epithelioid
trophoblastic tumor (ETT).
The most common types of gestational trophoblastic
disease occur when a sperm cell fertilizes an empty
egg cell or when two sperm cells fertilize a normal
egg. GTTs are characterized by trophoblastic
differentiation of the tumor tissue and production of
human chorionic gonadotropin (Hcg). This disease
becomes evident six to ten weeks after conception.
Most GTD tumors are benign, but some have the
potential to turn malignant.
Risk Factors
Maternal age: younger than 20 or older than 35 years
History of previous molar pregnancy
History of miscarriage
Hydatidiform Moles (molar pregnancy)
Partial mole: In partial mole the fertilized egg
contains the normal set of maternal DNA but double
the number of paternal DNA. Because of this, the
embryo only partially develops and does not become
a viable fetus. Most partial moles have a triploid
or near-triploid DNA content. The patients present
with vaginal bleeding or with missed abortion.
Macroscopically it shows tiny cysts measuring one
to three mm in diameter. Microscopically partial
moles show large irregularly shape hydropic villi
admixed with smaller fibrotic normal looking villi.
Some enlarge villi exhibit cistern formation and
trophoblastic lined invaginations and inclusions.
Presence of fetal blood vessels and nucleated RBCs
are helpful clues in differentiation from complete
mole. Immunohistochemistry for p57 shows nuclear
staining in cytotrophoblasts and villous stromal cells.
Partial moles are managed by suction curettage and
close follow-up to exclude persistent mole. The
disease status is monitored by serum HCG levels.
Complete mole: A complete mole develops when an
empty egg is fertilized by one or two spermatozoa

resulting in two complete male derived haploid
chromosome sets. The fertilized egg has no
maternal DNA and instead has two sets of paternal
DNA (46XX). A fetus does not form. The patient
usually presents with abnormal vaginal bleeding,
anemia, severe nausea or vomiting, abdominal
swelling, and high blood pressure at an early point
in the pregnancy. Macroscopically it shows diffuse
villous swelling resulting in appearance of grapes,
measuring up to two cm. Microscopically there is
markedly enlarge, hydropic villi with central cistern
formation. There is circumferential trophoblastic
proliferation around the villi, in addition there
may be cytological atypia of the separately lying
cytotrophoblasts and syncytiotrophoblasts (Figure
A). Immunohistochemistry for p57 shows absent
staining in cytotrophoblasts and villous stromal cells.
Differential diagnosis of complete mole includes
partial mole and early gestations. Early complete
moles with no risk factors may be treated on the same
lines as partial mole with close follow-up. High
risk lesions require single agent chemoprophylaxis
and if disease persists then these are managed by

Figure A: Complete mole, showing cisternal dilatation of the villi (↑) and
circumferential proliferation of trophoblastic cells around the villi (→).
Figure B: Choriocarcinoma, showing trimorphic trophoblastic
population, with cytotrophoblasts, intermediate trophoblasts and villous
syncytiotrophoblasts (→).
Figure C: Placental site trophoblastic tumor, shows characteristic
infiltrating growth, replacing the vascular wall (↑).
Figure D: Epithelioid trophoblastic tumor shows growth of epithelioid
trophoblasts which resemble squamous cells. There is deposition of pink
hyaline like material (↑) and tumor cells surrounding the blood vessels (→).
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combination chemotherapy or rarely hysterectomy
is needed. The treatment response of the disease
and disease status is monitored by serum HCG
levels. Complete hydatidiform mole carries a 15-20
percent risk of persistent gestational trophoblastic
disease and a two to three percent risk of gestational
choriocarcinoma.
Invasive mole: Invasive moles are locally invasive,
characterized microscopically by invasion of the
myometrium by trophoblastic tissue with identifiable
villous structures. These may be preceded by either
complete or partial molar pregnancy. They are
usually diploid in karyotype but may be aneuploid.
Microscopically, these lesions are characterized by
markedly edematous villi with associated sheets
and clusters of atypical trophoblasts within the
myometrium. Villi may be present in the vessel
and once vascular invasion has developed, it may
embolize to distant sites such as vagina, lungs, and
brain. Invasive moles have more aggressive behavior
than either complete or partial HMs, therefore treated
with chemotherapy or hysterectomy. Morbidity or
mortality can result, generally related to hemorrhage.
The disease status is monitored by serum HCG levels.
Gestational Trophoblastic Neoplasia
There are several types of gestational trophoblastic
neoplasia:
Choriocarcinoma: Choriocarcinoma is a malignant
tumor which may occur after molar pregnancy,
abortion, ectopic pregnancy, or normal pregnancy.
Most choriocarcinomas have an aneuploid
karyotype, and about three-quarters of them contain
a Y chromosome. Macroscopically it shows well
circumscribed hemorrhagic nodules. Microscopically
the lesion is characterized by admixture of cyto,
intermediate and syncytiotrophoblasts showing
marked degree of cytological atypia and nuclear
pleomorphism. In the background extensive
hemorrhage and necrosis seen (figure B).
Characteristically no villi present and presence
of villous alert the pathologist for an alternative
diagnosis. On immunohistochemistry the tumor cells
show positivity for HCG, hPL and SALL4.Ki67 is
more than 90 percent. The major differential diagnosis
includes persistent molar tissue, placental site
trophoblastic tumor and undifferentiated carcinoma.
Choriocarcinoma is managed by chemotherapy with
an overall disease-free survival is close to 90 percent.
Choriocarcinoma may metastasize to lungs, brain,
liver, pelvis, vagina, spleen, intestines, and kidney.
The treatment response of the disease and disease
8
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status is monitored by serum HCG levels.
Placental-site trophoblastic tumor: PSTT disease
mostly presents in reproductive age group usually
secondary to a term delivery, abortion, or molar
pregnancy. Most women present with irregular
bleeding. Macroscopically PSTT presents as discrete
mass or as polypoid appearance. Microscopically
PSTT has an infiltrative growth pattern and comprised
of sheets and aggregates of large polyhedral to
round cells with abundant amphophilic cytoplasm
and infiltrate into the myometrium. Pleomorphic
trophoblasts are also commonly seen (figure C). Most
tumors have fewer than five mitoses per 10 HPFs.
Ki67 index is usually less than 10 percent. They
are generally resistant to chemotherapy. Therefore,
hysterectomy is the basic primary treatment if the
tumor is confined to the uterus. However, about 35
percent of PSTTs have distant metastases at diagnosis.
The option of adjuvant chemotherapy is reserved for
patients who present with metastasis. Common sites
of metastasis include the lungs, pelvis, and lymph
nodes, brain, renal, and liver. The treatment response
of the disease and disease status is monitored by
serum HCG levels.
Epithelioid trophoblastic tumor: ETT is a subset of
PSTTs and arises from chorionic-type intermediate
trophoblasts. Morphologically, it shows nests and
cords of tumor cells surrounded by areas of necrosis
and calcification. The tumor cells are round to
polygonal with moderate to abundant eosinophilic
cytoplasm, distinct cell membranes and round nuclei.
Eosinophilic hyaline like material is seen in the center
of tumor nests which is an important diagnostic clue.
The tumor cells are usually seen around the vessels
and may resemble squamous cell cancer (SCC)
of the cervix therefore it is important to consider
this entity in mind when looking at SCC of cervix.
Mitotic activity is usually low (figure D). Differential
diagnosis includes PSTT, choriocarcinoma and
squamous cell carcinoma. Immunohistochemistry
shows positivity for p63 and inhibin. Ki67 is usually
less than 10 percent. Hysterectomy is the preferred
treatment. Chemotherapy is reserved for resistant
disease or with evidence of metastasis. Its clinical
behavior appears to be closer to that of PSTT than
to choriocarcinoma. It has a spectrum of clinical
behavior from benign to malignant. About 10 percent
of cases behave in a malignant manner and may
metastasize, usually in the lungs.
FIGO Stages of GTN:
I: Disease confined to the uterus
II: Gestational trophoblastic tumor extends outside

JUNE 2022
of the uterus, but limited to the genital structures
(adnexa, vagina, broad ligament)
III: Gestational trophoblastic tumor extends to the
lungs, with or without known genital tract
involvement
IV: All other metastatic sites
Prognostic Factors:
The prognosis for cure of patients with GTDs is
good even when the disease has spread to distant
organs, especially when only the lungs are involved.
Therefore, the traditional staging system has limited

VOL 47, ISSUE 1
prognostic value. The probability of cure depends on
the following:
Histologic type (invasive mole or choriocarcinoma).
Extent of spread of the disease
largest tumor size.
Level of serum beta-hCG.
Duration of disease from the initial pregnancy event to
start of treatment.
Number and specific sites of metastases.
Nature of antecedent pregnancy.
Extent of prior treatment.

Acrania-Exencephaly-Anencephaly Sequence/
Spectrum: Radiological Features on Antenatal
Screening
Dr Sundas Basharat and Dr Shayan Anwar
Radiology

The term Acrania-Exencephaly-Anencephaly
sequence encompasses separate pathological entities
which are in fact interchangeably diagnosed at
different periods of gestation and may be difficult to
distinguish.
Definitions and Pathophysiology
Acrania: refers to non-development of cranial
vault, associated musculature and dura secondary to
defective migration of mesenchymal cells beneath the
ectodermal layer after closure of anterior neuropore
around fourth week of gestation.
Exencephaly: With acrania regarded as an
antecedent, absence of cranial vault and associated
structures impair the normal differentiation of cerebral
parenchyma resulting in relatively morphologically
normal appearing to disorganized cerebral tissue
referred to as exencephaly.
Anencephaly: Associated with acrania
characterized by complete absence of cerebral
parenchyma occurring as a result of defective
closure of anterior neuropore around 4th week of
gestation at the level of forebrain and midbrain.
Normal fusion is however seen at hindbrain and
cervical cord level.

Acrania-Exencephaly-Anencephaly sequence
refers to the progression of acrania with exencephaly,
resulting in degeneration and progressive destruction
of cerebral parenchyma secondary to mechanical
trauma and exposure to the amniotic fluid with almost
complete disintegration of cerebral tissue after 14th
week referred to as anencephaly. Disintegrated brain
tissue may be visible within the amniotic fluid as
echogenic floating particles.
Radiological features on antenatal scans
Acrania: Antenatal diagnosis of acrania is established
after 11 weeks onwards since the ossification of
fetal cranial vault typically starts after nine weeks.
Characterized by absent ossification of predominantly
frontal bones on axial and coronal sections, cerebral
hemispheres may be seen surrounded by a thin
membrane. (Figure 1-3)
Exencephaly: Considered as an antecedent to
anencephaly. Characterized by absent fetal cranial
vault with exposed fetal brain seen floating within
the amniotic fluid, loss of cerebral tissue is seen to
variable extent. Absence of nasal bone may also be
seen. (Figure 1)
Anencephaly: Considered at the extreme end of
9
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neural tube defects spectrum incompatible with life.
Characterized by absent fetal calvarium and brain
tissue cephalad to the orbits. “Frog eye” appearance
may be seen secondary to absence of brain tissue
cephalad to the bulging orbits in coronal plane.
Variable presence of brainstem and cerebellum may be
seen. (Figure 2,3)

Figure 3: Another example of acrania with absent brain parenchyma
suggestive of anencephaly.

Figure 1: Image from antenatal scan reveals acrania with dysmorphic
brain (Blue arrows) above the fetal face suggestive of acrania with
exencephaly.

Prognosis and Treatment:
Considered as a cranial neural tube defect,
incompatible with life.
Most cases result in still birth, however infants who
survive usually die within hours, days or few weeks
after birth. Early diagnosis is therefore essential for
counseling of the parents and planning for early
termination of pregnancy.
Prevention:
With an increased risk of recurrence in future
pregnancies, folic acid therapy may be considered
essential for prevention.

Figure 2: Image reveals absence of cranial vault and brain with
protruding orbital structures giving “ frog eye appearance”(blue arrow)
suggestive of acrania with anencephaly.

Conclusion:
Sonographic diagnosis of anencephaly and
its antecedents in the Acrania-ExencephalyAnencephaly Sequence is possible with the help
of high-resolution sonography as early as 11th week
of gestation with an accuracy reaching almost 100
percent at 14th week of gestation.

Minimally Invasive Tissue Sampling (MITS)
A New Way to Investigate Cause of Death In
Resource-constrained Countries
Dr Saman Amin and Zeeshan Uddin
Histopathology

Minimally invasive tissue sampling (MITS) consists
of a series of post-mortem punctures using fine biopsy
needles aiming to obtain tissue samples and body
fluids from a corpse within the first hours after death,
which are then submitted for a thorough pathological,
molecular and microbiological investigation of the
10

underlying cause of death (Figure 1).
MITS is proposed as an alternative to complete
diagnostic autopsy (CDA). CDA is a complex
procedure and needs resources, infrastructure and
pathology expertise. It is also limited by deaths
occurring outside of formal health system premises
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qualified medical
personnel and
are frequently
buried or
cremated without
a documented
medical history,
before an
evaluation of the
cause of death
can be conducted;
many times,
a
b these deaths are
not counted at
Figure 1: Right lung is being sampled by Bart monopty biopsy needle (a). The sample for histopathology is being sent in formalin (b). all. As a result,
overall mortality
and lack of interest from clinicians and relatives.
is underestimated, and because of a variety of
It is important to identify cause of death so that
assumptions and dependence on non-specific data,
government and health institutions can better plan and
calculations of the local, regional and global burden
prioritize their efforts, ultimately saving lives around
of specific causes of mortality result in dramatically
the world.
conflicting numbers and substantial uncertainty.
MITS was developed in 2013 by the Barcelona
Credible and accurate mortality data would enable
Institute for Global Health (ISGlobal). It is carried out
policymakers, stakeholders, donors to effectively
by trained pathologists and/ or technicians using fine
target the leading causes of childhood mortality for
needles to collect small amounts of tissue and fluid
interventions, a critical component for achieving
from key organs.
the Sustainable Development Goal for eliminating
MITS has many advantages such as:
preventable childhood deaths.
• Non-disfiguring, compared to CDA.
• Relatively low cost.
Child Health and Mortality Prevention Surveillance
• Performed quickly.
(CHAMPS) An international disease surveillance
• Technically much more feasible – Simple
network focused on child mortality funded by the
and easy to perform by minimally trained
Bill & Melinda Gates Foundation and coordinated
by Emory University and the US Center for Disease
personnel in remote areas.
Control (CDC). The CHAMPS network is tracking
• Relatively accurate – Validated through
track the causes of under-5 mortality and stillbirths at
observational studies across all age groups.
sites in sub-Saharan Africa and South Asia through
The minimally invasive tissue sampling (MITS)
epidemiologic surveillance of under five deaths and
procedure, formerly known as the minimally
still births utilizing MITS, laboratory diagnostics
invasive autopsy (MIA), was developed as an
including conventional and advanced histopathology
approach to reduce uncertainty around cause of
and molecular screening of various pathogens, verbal
death determination in high mortality settings, where
autopsy, and available clinical and demographic
clinical and postmortem diagnoses are nearly always
data. Recently Pakistan has been selected as a site
unavailable, and where performance of complete
for CHAMPS with Aga Khan University leading the
diagnostic autopsy would not be feasible. The
project.
procedure uses biopsy needles to obtain post-mortem
samples of lung, brain, liver and other key organs
Another project called The Project to Understand &
for histopathologic, microbiologic, and molecular
Research preterm Pregnancy Outcomes and Stillbirth:
examination to help determine cause of death.
South Asia (PURPOSe) was launched to determine the
main causes of death for still births and preterm (Less
Childhood Mortality and Role Of Mits:
than 37 weeks gestation) infants admitted to the NICU
or delivered and cared for in selected hospitals in
Despite reductions over the past two decades,
Pakistan and India study sites. Target sample size for
childhood mortality remains high, particularly in
Pakistan was 350 stillbirths and 350 preterm neonatal
low-income settings in sub-Saharan Africa and south
deaths. With a neonatal mortality rate of 15-20
Asia. In lower- and middle-income countries (LMIC),
percent, it was estimated that we need to recruit 2,500
individuals often die without having been seen by
11
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women with preterm live births in order to evaluate
350 preterm neonatal deaths.

plate malformation and a few showing features of
storage disorder (Figure 3). Brain samples were
mostly unremarkable histologically. Like other
studies, lung tissue was found to be the most valuable
for determining the COD. The sample preservation
was adequate in most cases except in a few cases of
still births where the samples were autolyzed due to
marked maceration of fetus.

PURPOSe – MITS acceptance rate was 74 percent for
stillbirths and 36 percent for preterm neonatal deaths.
Success rate in obtaining the pathology samples was
comparable to other reported studies. Because of size,
location and bilaterality, obtaining lung samples was
in general more successful than other organs. Several
histopathological findings were seen in the MITS
samples of PURPOSe particularly in lungs including
amniotic fluid aspiration, intra-alveolar hemorrhage,
hyaline membrane disease, bronchopneumonia/
pyogenic pneumonia etc (Figure 2). Liver showed
cases with extramedullary hematopoiesis, ductal

In conclusion, MITS is a reliable alternative to
CDA for determining the cause of death in resource
constrained settings and relatively conservative
countries like Pakistan. Since it is based on blind
sampling of various key organs, its accuracy may be
further increased by adding radiological support.

a

b

Figure 2: MITS histopathology sample of lung showing cases of hyaline membrane disease (a) and amniotic fluid aspiration (b).

a
Figure 3: MITS histopathology sample of liver showing examples of ductal plate malformation (a) and storage disorder (b).
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Laboratory Guideline for Detection,
Interpretation and Reporting of Maternal Cell
Contamination (MCC) in Prenatal Analysis
Samina Ghani
Molecular Pathology

The potential presence of maternal cell contamination
(MCC) in chorionic villus or amniotic fluid
samples poses a serious preanalytical risk for
prenatal misdiagnosis. Association for Molecular
Pathology (AMP) guidelines available for the
entire testing process within a clinical laboratory,
from preanalytical, through the analytical and
postanalytical phases of analysis. Together with
good laboratory practices and existing standards
and guidelines for molecular genetic testing,
these guidelines can help provide accurate genetic
information and minimize the potential of diagnostic
error.
Prenatal Guidelines
1. It is recommended that MCC analysis be
performed in parallel with diagnostic testing,
regardless of the genetic disorder or its mode
of inheritance.
2. All pertinent intake information including
clinical, family, and testing history, should be
provided to the laboratory, along with the
prenatal sample.
3. Information regarding multiple
gestations should be available to the
laboratory, along with the prenatal sample,
due to the risk of potential co-fetal
contamination from a twin.
4. Only a maternal peripheral blood is strictly
required for MCC testing. Paternal samples
are not helpful for MCC analysis.
5. Backup cultures should be readily available
for repeat or confirmatory testing if MCC is
detected in an uncultured specimen.
6. Every effort should be made to include the
prenatal sample(s) in the earliest available
assay setup and to prioritize the prenatal
samples into testing.
7. It is important that only one prenatal test
sample be handled at any one time to ensure
accuracy and prevent a potential mix-up of
samples at this stage of analysis.

Technical Guidelines
1. Maternal specimen should be tested and
analyzed for MCC concurrently within the
same analysis to allow for a direct comparison
of results.
2. The performance characteristics of these
assays must be validated for the intended
purpose of MCC studies in each laboratory
before implementation into clinical testing.
3. Tetranucleotide/pentanucleotide markers are
preferable monitors for MCC over smaller
repeat markers due to the superior fidelity,
robustness of PCR amplification, accurate
measurement of repeat units by fragment
analysis, distinguishable alleles with a high
discriminative capacity, and intergenerational
stability among individuals in the general
population.
4. PCR stutter peaks (caused by replication
		 slippage during PCR amplification) that are
		 the size of the repeat unit of a maternal allele
		 should be considered noninformative for
		MCC
5. It is recommended that two to three 		
		 informative microsatellite markers reflecting
		 clearly definable, separate maternal and fetal
		 genotypes from among a panel of
		 approximately seven to ten markers be used to
		 assess the presence of MCC in a prenatal
		sample.
6. At least five percent MCC must be routinely
		 detectable by the clinical laboratory. This
		 percentage is recommended as the upper
		 limit based on the fact that erythrocyte
		 admixture of just a few percent is readily
		 visible by eye, and that incorrect
		 interpretation of a PCR-based diagnostic
		 prenatal test has been reported even at a
		 level of one percent to two percent MCC,
		 six with increasing likelihood at higher
		percentages.
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Reporting Guidelines
1. The prenatal diagnostic results should not
		 be released before the MCC analysis is
		completed.
2. The sensitivity of the MCC assay should be
		 indicated on all issued MCC reports.
3. The presence of very small peaks, possibly
		 indicating low-level MCC at or below the
		 validated level of detection for the MCC
assay or below the threshold of sensitivity
of the clinical assay, may require
acknowledgment on the reports. Comments
in the context of such reports may include
phrases such as “significant maternal cell
contamination not detected,” or “maternal cell
contamination is unlikely to have interfered
with the reported fetal result.”
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Figure: A practical testing algorithm for prenatal samples.

Importance of Antenatal Red Cell Screening
for Assessment of Maternal Alloimmunization
Dr Fatima Farhan and Dr Hasan Hayat
Haematology & Transfusion Medicine

Screening is an important component of initial healthrisk assessment with major objective of reducing
morbidity and mortality. The aim of antenatal
screening is to ensure safety of the mother and the
fetus by identifying the need for timely intervention
and management of the pregnancies at risk. One
of the main hematological emergencies that arise
during pregnancy is hemolytic disease of the fetus
and newborn (HDFN) due to immune mediated
causes like Rh or ABO blood group incompatibility
and non-immune cause due to hemoglobin structural
variants or hemoglobinopathies. Antenatal screening
has become an important component of the standard
routine laboratory panel testing nowadays that is
recommended at the first antenatal (booking) visit for
every pregnant woman.
HDFN arises due to alloimmunization against fetal
red cell antigens such as A, B, Rh antigens (anti-D,
anti-E and anti-c ), Kell, Kidd and Duffy which are
recognized as foreign antigens by the mother, leading
to formation and transplacental passage of maternal
IgG antibodies and destruction of the fetal red blood
cells causing severe anemia and hemolysis. Most
of the cases of severe HDFN are caused by anti-D
antibody affecting 1 in 1200 pregnancies, leading to
14

kernicterus, severe edema, ascites, heart failure and
death (hydrops fetalis). ABO incompatibility is more
commonly encountered in almost 15 percent of all
pregnancies but HDFN occurs in only one percent of
such pregnancies and is caused by IgG antibodies of
blood group O mothers.
The antenatal red blood cell antibody screening
protocol recommends screening of all pregnant
women for blood group (ABO and Rh) at the first
antenatal clinic visit in the first trimester. Nonsensitized Rh-negative mothers who screen negative
for antibodies are screened for antibodies again at
28th week of gestation and at delivery. In mothers
with positive antibody screen, the antibody titers are
determined and then serially monitored throughout
the pregnancy. The non-sensitized Rh-negative
mothers who screen negative for Rh antibodies are
given 100 microgram of anti-D immune globulin
prophylaxis at 28th and 34th week of gestation to
prevent maternal red cell alloimmunization. Another
approach is to give single dose of 300 microgram
at 28th week of gestation. If primary immune
response to the D antigen has occurred, maternal
administration of anti-D immune globulin will not
prevent a rise in titer, and anti-D immune globulin
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should not be administered to sensitized women.
Interpretation of antibody titration results by
Indirect Antiglobulin Test
The antibody titer is commonly determined by
indirect antiglobulin test (IAT). It is performed by
incubating the maternal serum with cells having
antigen against which mother has developed
antibodies (for example Rh-D positive red blood
cells in case of RhD alloimmunization) and IgG
antiglobulin reagent at 37oC. The critical antibody
titer is 1:16 – 32 for anti-D and 1:8 for anti-K. If
titration is 1:16, repeat titration at 18-20 weeks of
gestation. If titer is < 32, it should be repeated at four
weekly intervals, starting from 16-20 weeks gestation.
If titer is ≥32, the fetal anemia should be assessed for
HDFN by velocimetry of fetal middle cerebral artery
by color Doppler imaging after 16 weeks of gestation.
Paternal zygosity of the at-risk fetus for being affected
by HDFN should be confirmed by noninvasive
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method of detecting cell-free DNA in the maternal
plasma by PCR.
The introduction of routine antenatal red cell
screening has changed the overall spectrum of HDFN
in the last few decades. An effective, timely, reliable,
cost-effective antenatal screening programme can help
improve patient outcomes. This has allowed patients
to make reproductive choices and to monitor the
pregnancy for complications. The timely prophylaxis
with Rh immune globulin has decreased the overall
incidence of Rh-D alloimmunization in pregnancy
and reduced the need for repeated intrauterine blood
transfusions. The utility of diagnostic techniques,
starting from detecting allo-immunized pregnancy
by maternal blood group typing, antibody screening/
identification and titration, to the quantification
of feto-maternal hemorrhage by Kleihauer-Betke
testing or by flow cytometry has helped achieved the
main outcome of management, which is a successful
pregnancy and delivery of a healthy newborn.

Maternal Screening for the Prevention of Early
Onset Group B Streptococcal Disease in Neonates
Dr Syeda Rija, Dr Mehreen Shahid, Dr Adan Zubair and
Dr Moiz Khan
Microbiology

Group B streptococcus (GBS) is a facultative
pathogen found in gut and vaginal tract of some
women. The primary reservoir is the gastrointestinal
tract which provides the source for vaginal
colonization. GBS is considered as the most frequent
cause of early onset infections in newborn infants
ranging from asymptomatic infection to pneumonia,
septicemia and meningitis. Early onset of disease is
usually related to maternal colonization of GBS in
the genitourinary tract, with increased chances of
vertical transmission during labor or after rupture of
membranes.
The overall prevalence of GBS vaginal colonization
in pregnant women ranges from 17 percent to
22.6 percent. The risk factors associated with
transmission of infection include GBS bacteriuria
during pregnancy, intrapartum fever, preterm labor
at <37 weeks of gestation, previous infant with
GBS infection or prolonged rupture of membranes
for >18h5. Universal prenatal screening of mothers

through vaginal/ rectal cultures coupled with targeted
intravenous intrapartum antibiotic prophylaxis has
shown efficacy in preventing neonatal GBS infections.
For the detection of GBS colonization culture
technique remains gold standard for identification of
infection however, this method requires 18-72 hours
for final organism identification. Therefore, culturebased technique is only feasible for antepartum
screening and not for intrapartum testing. Another
modality for the detection of GBS infection is Real
time Polymerase chain reaction (RT-PCR) which has
shown to be more sensitive and specific than culture
techniques. Recently, an Xpert GBS assay (Cepheid),
which is a commercial RT-PCR test has become
available which is more sensitive and specific than
culture screening.
Culture based method:
A culture of lower vagina and anorectal swab is the
most employed method for GBS screening. These
15
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swabs are placed in non-nutrient transport media
after collection and should be kept at ~4oC. Enriched
culture media such as Todd-Hewitt broth with
nalidixic acid and colistin, are recommended which
can be sub-cultured on chromogenic agar or selective
media.
Molecular methods:
RT-PCR has been the conventional molecular method
for GBS screening. Recently a modification of this
method has been introduced namely the Xpert GBS
assay test with sensitivity of around 89 percent
according to a randomized control trial. The test

VOL 47, ISSUE 1
is fully automated involving DNA intensification,
cleaning of nucleic acids and detection of the required
cfb gene sequence with a reporting time of 50
minutes.
In conclusion, GBS colonization of mothers can
be screened through the conventional culture
technique which is the gold standard. However,
owing to recent advances newer diagnostic methods
such as RT-PCR and Xpert GBS assay offer prompt
recognition of GBS infection which are more
sensitive and specific than conventional culturebased screening.

Molecular Analysis of Alpha Thalassemia by
MLPA
Nazneen Islam, Kahkashan Imam, Sonana Riaz,
Drs Asghar Nasir and Zeeshan Ansar Ahmed
Molecular Pathology

Introduction
The Alpha thalassemia is the inherited disorder
of ά globin gene, which encompasses all those
conditions in which deficit production of ά globin
chain of hemoglobin (Hb) which contain normally
two ά-like and two β like globin chain (HbA). Due
to underproduction of ά globin chain, γ and β globin
chain synthesized excessively for compensation
during fetal and adult life respectively, called
Hb Bart’s (γ4 tetramers in fetus) and HbH(β4
tetramers in adult).Individuals having mutation in
one allele of globin gene on chromosome ,are said
to have ά thalassemia trait, they may associated
with mild anemia or with normal hemoglobin.
Compound heterozygotes and some homozygotes
for ά thalassemia have moderately severe anemia
characterized by presence of HbH disease. In neonatal
period some individual who make very little or no
α globin chains have a very severe form of anemia
which, if untreated, causes death called the Hb Bart’s
hydrops foetalis syndrome.
Genetics of Alpha Globin
Alpha globin gene present on chromosome16
(16p 13.3) whereas Beta globin gene present on
chromosome11 (11p 15.4). There are two functional
alpha genes present in chromosome 16, which are
16

arranged as following described in figure 1. The size
of cluster gene is 70 kb which consist of three pseudo
gene ψ, έ,ά2, and ά1 and four functional genes, έ,ά2,
ά1 and φ, in alpha gene there are 3 exon and 2 introns.
There are about 10 variable number of tandem repeats
are located around the alpha globin gene locus. Two
alpha genes lie adjacently to each other. As each
diploid cell contains two sets of each chromosome,
hence there are four alpha globin alleles are present in
normal individual.
Epidemiology
The prevalence of alpha thalassemia is also like others
common globin gene disorder (β thalassemia and
sickle cell trait), it has high frequencies throughout all
tropical and subtropical of the world. In some areas,
the carrier frequency of α thalassemia may be as high
as 80-90 percent of the population, almost at fixation.
Of all globin disorders, α thalassemia is the most
widely distributed and therefore many individuals in
these areas have interacting combinations of these
variants (e.g. both α and β thalassemia). Due to
differences in the interactions between the various
molecular defects underlying α thalassemia, HbH
disease is predominantly seen in South East Asia, the
Middle East and the Mediterranean. Similarly, the
Hb Bart’s Hydrops fetalis syndrome is predominantly
seen in South East Asia.
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Etiology of ά thalassemia on Molecular Basis
Alpha globin synthesis in normal healthy individual is
regulated by four ά globin genes two on each copy of
chromosome and this one genotypical express as άά/
άά. These genes expression is dependent on remote
regulatory elements (named Multispecies Conserved
Sequences or MCS-R1 to R4) located far upstream of
the globin genes in the introns of a flanking, widely
expressed gene. Deletion of genes one (-α) or both (--)
α genes from the chromosome is most frequent cause
of alpha thalassemia. Occasionally point mutations
in critical regions of the α2 (α r α) or α1 (αα r) genes
may cause, so-called, non-deletional α thalassemia.
Very rarely, α thalassemia results from deletion of
the MCS-R regulatory elements (written as (αα)r),
in all of these deletions MCS-R2 is always removed
and thus appears to be the major regulatory element.
When a mutation(s) completely abolishes expression
from a chromosome this is called α0-thalassaemia
and when the mutation(s) only partially down regulate
expression from the chromosome this is called α+thalassemia.
Genotype/Phenotype Correlations
There is up till now more 128 different genetic
defects reported,14 which causing ά thalassemia and
there is increasing number of potential interacting
mutations, the clinical phenotypes (broadly classified
as α thalassemia trait, HbH disease and Hb Bart’s
hydrops foetalis) resulting from the interactions
between these various molecular defects can be
simply summarized as in Table 1. The severity of
the clinical phenotype correlates very well with the
degree of α globin chain deficiency. An important
additional point is that, in general, interactions
involving non-deletional forms of α+-thalassemia
result in a more severe phenotype than in those with
deletional forms of α+-thalassemia.
α Thalassemia trait
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basis of the disease. Patients with non-deletional types
of HbH disease are more severely affected than those
with the common deletional types of HbH disease.
Hb Bart’s Hydrops Foetalis Syndrome
Infants with the Hb Bart’s hydrops foetalis
syndrome have the most severe deficiencies in α
globin expression. While it most frequently results
from the inheritance of no α globin genes from either
parent, in some cases it results from the inheritance
of a severe nondeletion mutation from one parent and
no α genes from the other. Patients on the borderline
between severe HbH disease and Hb Bart’s hydrops
foetalis syndrome are said to have HbH hydrops
syndrome.
Molecular analysis
Last few decades it has becomes increasingly
possible to diagnose alpha thalassemia very
accurately and identify the precise defects
underlying these disorders using a variety of
molecular techniques. Ultimately, most α globin
chain rearrangements have been characterized by
MLPA and DNA sequence analysis. However, for
today’s diagnostic demands these techniques are
far too laborious to apply in each case, and from
the original work defining these mutations, rapid
screening assays have been developed. For suspected
but currently unknown rearrangements, Southern
blotting or MLPA analysis may be used. Southern
blot is the classical method to detect deletions
causing α-thalassemia [15-19]. More recently
Multiplex Ligation-dependent Probe Amplification
(MLPA) is used, based on ligation of multiple probepairs hybridized across a (usually large) region of
interest (figure 2), followed by semi-quantitative
amplification using universal tag PCR primers and
subsequently fragment analysis.
Methods

Those individuals are carriers (heterozygotes) of
α thalassemia, whatever the molecular basis, are
clinically asymptomatic and the diagnosis is often
established during a regular health check or during
antenatal screening.
HbH disease
HbH disease is most frequently seen in patients
who are compound heterozygotes for two different
mutations or less frequently homozygotes for a
moderately severe molecular defect. The severity of
the clinical features is clearly related to the molecular

Multiplex Ligation-dependent Probe Amplification
(MLPA) is performed on blood after DNA extraction,
for analysis alpha thalassemia we identified deletion
and duplication of ά globin gene, it consists on four
steps procedure which amplify its tested product in
two days. The steps are follows:
1) Hybridization Reaction (Day-1)
2) Ligation Reaction (Day-2)
3) PCR Reaction Day-2)
4) Separation of Amplified product by Capillary
Electrophoresis
17
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Phenotype

Genotype

Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome
Hemoglobin H (HbH) disease

Loss of all 4 α-globin genes
Loss of 3 α-globin genes
Loss of 2 α-globin genes either in cis (--/αα, α0 carrier)
or in trans(-α/-α)
Loss of 1 α-globin gene (-α/αα, α+ carrier)

α-thalassemia trait
α-thalassemia silent carrier

Figure 1: The structure of the α-globin gene cluster on chromosome 16.
Adopted from Harteveld and Higgs Orphanet Journal of Rare Diseases 2010, 5:13
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Figure 2: The principle of Multiplex Ligation dependent Probe Amplification (MLPA).
Adopted from Harteveld and Higgs Orphanet Journal of Rare Diseases 2010, 5:13
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Table 1: Alpha-thalassemia mutations in different ethnic groups
Adapted from Barbara J. Bain, Haemoglobinopathy Diagnosis 2nd edition 2006 {Bain, 2006 126/id}
Ethnic Group
India

Middle East

South-East Asia

Type of
Thalassemia
α+

Mutation(s)

Occurrence

- α3.7

Common

- α4.2

Less common

α Koya Dora α

Relatively rare

α IVS I-117 α

Relatively rare

α+ - α0

α PA3(AATA- -) α

Also found in Hindustani from Surinam

α0

- - MED 1

Common in Iran, Palestinians, Arab population

α+

- α3.7

Common in Iran, Palestinians, Arab population

α+ - α0

α PA1(AATAAG) α

Relatively common in Arab population

α0

- - SEA
- - FIL
- -THAI

Most common deletion among Asians world wide
Mainly in Philippinians
Common among Thai

α+

- α3.7
- α4.2
ά Constant Spring α
α Suan Dok α
α Quong Sze α
α Pakse α
α init A-G α
α init -TG α

Relatively common
Relatively rare
One of the most common non-deletion variants in Chinese
Highly unstable α-chain
Highly unstable α-chain
Highly unstable α-chain, found in Thai, Laotian
Common in Vietnam
Common in South-East Asia
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Kleihauer – Betke Test: An Important Yet
Underrated Tool for Prevention of
Erythroblastosis Fetalis
Dr Rabiya Jawed
Haematology & Transfusion Medicine

All human beings are born with a blood group (A,
B, AB or O), which can be Rh positive (+ve) or Rhnegative (-ve). It may happen that a Rh-negative mother
has a baby with an Rh-positive father, resulting in an
Rh-positive baby. By chance, the cells of the baby can
enter maternal circulation and can trigger an immune
response, resulting in antibodies against Rh-positive
fetal blood cells. In the subsequent pregnancy, these
maternal antibodies can attack the fetal cells when they
cross the placenta, and destroy the Rh-positive fetal
red blood cells. Destruction of fetal red blood cells
can cause fatal anemia and jaundice in the neonate, a
condition termed erythroblastosis fetalis, or Hemolytic
Disease of the Fetus and newborn (HDF/N).
The fetal and maternal blood circulations run separate
to each other in the placenta, however this fetal blood
can also enter the maternal circulation in conditions
such as abdominal trauma, anterior placental
location or uterine tenderness. Termed fetomaternal
hemmorhage (FMH), this unique complication of
pregnancy can harm the fetus in Rh negative mothers.
The presence of Rh positive fetal blood can induce
anti-D antibodies in maternal circulation. These
anti-D antibodies can enter fetal circulation and
destroy the Rh-positive blood cells of the fetus.
The Kleihauer Betke Test is used to quantify the
presence of fetal blood in maternal circulation. This test
detects fetal blood in maternal circulation at a sensitivity
of 5mL, that is if the quantity of fetal blood in maternal
circulation is less than 5mL, then the KB test is not
able to detect it. Rather than positive or negative, the
Kleihauer Betke test reports the total amount of fetal
blood in maternal circulation. The working principle of
this test is based on the different types of hemoglobin
that exists in maternal (HbA, HbA2) as compared to
fetal blood (HbF). Fetal hemoglobin is much more
resistant to acid elution than maternal hemoglobin, hence
maternal hemoglobin washes away when exposed to
20

acid. The slide is then washed, stained and viewed under
the microscope. If fetal cells are present, they will appear
red as compared to maternal blood cells, which have lost
their hemoglobin. The visualised cells are then counted
to quantify the fetal blood. A laboratory technologist
counts up to 2000 cells, typically in eight to ten high
power fields
The counted values are reported as a percentage as follows:
%fetal red blood cells =
Fetal red blood cells counted in slide X 100%
Total Maternal Cells
The volume of FMH i.e., the number of fetal cells with ratio
to total maternal circulation is then calculated as follows:
Volume of FMH =
Number of fetal cells x 5000 (maternal blood volume)
100
Apart from quantifying fetal blood cells in maternal
circulation, this test can also be used to assess the
dose of prophylactic Immunoglobulin (RhIg) to be
administered to a pregnant Rh-negative mother, within
72 hours of delivering a Rh-negative fetus. The dose of
RhoGAM (Anti-D antibody) is calculated as follows:
Vial requires: Volume of FMH
30 (ml for whole blood)
The administration of anti-D antibody is essential
for the prevention of fatal anemia and jaundice of
the newborn during subsequent pregnancies in a Rhnegative mother. While Hemoglobin F quantification
by Flow Cytometry is considered more sensitive for
HbF detection in maternal blood, the relatively low
cost of Kleihauer Betke Test makes it an important
tool for assessment of FMH and administration of
Anti-D antibodies in mothers belonging to lower
socioeconomic brackets in the world.
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Study of DMD Gene for Exon/s Deletion/
Duplications by Multiplex Ligation-Dependent
Probe Amplification in Prenatal Samples
Sonana Riaz, Sana Sajid, Dr Asghar Nasir and
Dr Zeeshan Ansar
Molecular Pathology

Prenatal testing plays a vital role in determining
during pregnancy if the fetus has a likelihood to be
born with a genetic condition or congenital disability.
It helps the clinician select the best available option
for the management of the pregnancy and for the
baby’s benefit. Today, clinical laboratories offer
several types of prenatal testing platforms depending
upon which trimester of pregnancy the mother is
and the condition being referred. Molecular testing
for fetal diagnosis is performed on amniocentesis
or chorionic villous biopsy samples obtained during
pregnancy’s first and second trimesters.
Duchene muscular dystrophy is an X-linked recessive
disorder affecting approximately 1 in 3,500 live male
births worldwide. DMD gene (ID 1756) is located on
the short arm of chromosome X at cytoband Xp21. It
is the largest known protein-coding gene in the human
genome. DMD gene consists of 79 exons and spans
a region of 2.2 million base pairs. DMD gene was
discovered in 1986 by researchers using the positional
cloning approach, which in the mutated form leads
to the development of Duchene Muscular Dystrophy
disorder. DMD gene provides instructions for forming
a protein called dystrophin, a large 427 kDa rod shape
protein that resides in the cytoplasm. Primarily this
protein is found in the cardiac and skeletal muscles. In
addition, a small amount of dystrophin protein is also
identified in neuronal cells of the brain.
Pathogenesis and Clinical Features of DMD
Patients with muscular dystrophy have little or no
dystrophin. It has been suggested that this results in
the disruption of muscle membranes, which alters
calcium channel activity, thereby strongly increasing
intracellular calcium concentration. Dystrophin
absence leads to harmful effects, such as muscles
becoming weak and prone to damage, initiating

progressive loss of muscle tissue and function. Fibrous
tissue begins to form in the muscle, and inflammation
sets in starting in early childhood. Affected patients
have a massively reduced life expectancy and a poor
functional prognosis. In most cases, DMD is due to
frame-shift mutations in the DMD gene, leading to a
complete absence or low dystrophin protein levels (no
more than three percent normal levels).
Molecular Diagnostic approach to Screen for DMD
Molecular testing is a valuable tool for confirming
the clinical diagnosis of DMD in affected children.
In addition, through prenatal screening, one can
determine whether a developing fetus carries
specific genetic abnormalities. For this purpose,
ultrasonography, blood tests, amniocentesis, CVS, and
cell-free DNA analysis are more frequently done in
the first or second trimester. Screening tests further
enable physicians to advise required diagnostic tests
to rule out genetic abnormalities. DMD patients who
are suspected of dystrophinopathy based on clinical
signs and an elevated serum creatine kinase (CK)
level are tested for mutations in the DMD gene, which
also obviates the need for a muscle biopsy. Identifying
the causative mutation in an affected individual and
recommendations for genetic counseling of family
members allows the carrier and prenatal testing to be
performed as appropriate. According to the scientific
literature, in approximately 65 percent of cases of
DMD (and 85 percent of cases of BMD), deletion
of one or more exons is observed. Furthermore,
duplication of one or more exons is reported in six–
ten percent of cases of both DMD and BMD. The
remaining cases are primarily due to point mutations,
small insertions/deletions, or splice site changes.
Since whole exon deletions are the predominant
type of mutation in the DMD gene (65 percent), an
initial screen that detects most deletions should be
21

JUNE 2022

VOL 47, ISSUE 1

the minimum diagnostic test offered in such cases.
Currently, MLPA is used in many clinical laboratories
worldwide for the genetic diagnosis of DMD.
Diagnostic Test for Prenatal DMD by MLPA
(Multiplex Ligation-Dependent Probe
Amplification)
Prenatal testing for DMD is generally carried out on
amniotic fluid and chorionic villus biopsy specimens.
Chorionic villous sampling is typically accomplished
between 10 and 12 weeks of pregnancy through
an ultrasound-guided procedure. Figure 1 shows
Chorionic villous Sample.
Figure 2: Maternal cell contamination check MCC

Figure 1: Chorionic villous sample

In contrast, amniocentesis for collecting the
amniotic fluid sample is performed between 15 and
20 weeks of gestation. Subsequently, amniotic fluid
samples are processed for fetal cell culture in tissue
culture flasks. After obtaining confluency, cells
are harvested, and DNA is extracted for mutation
analysis. In the case of chorionic villus biopsy,
villi are separated from maternal tissue under a
dissecting microscope. Cleaned villi are used for
DNA extraction and further processing for mutation
analysis. Figure 2 shows diagram of Maternal cell
contamination check MCC which is performed
through STR analysis once MCC results are obtained
clear test is proceed further.
MLPA is one of the molecular techniques that can
22

quickly and reliably identify small deletions and
duplications below the resolution of karyotyping
and FISH techniques. MLPA is based on
fluorescently labeled probes that target the region
of interest of the genome. Each probe set consists
of two oligonucleotide DNA fragments that are first
hybridized to their specific targets in the DNA,
ligated using ligase enzyme, and subsequently,
PCR amplified. The amplification products are
separated by capillary electrophoresis, and the
relative quantity of each fragment is determined.
MLPA testing kits manufacturer provides software
for prompt analysis of MLPA data. Figure 2
shows a typical MLPA reaction. Following DNA
denaturation, a mix of MLPA probes is added to
the sample tube for ligation. Each probe in the
MLPA probe mix has a unique amplicon length,
typically ranging between 130 and 500 nucleotides.
All ligated probes are amplified simultaneously
using the same PCR primer pair. One of the two
PCR primers is fluorescently labeled, enabling
the amplification products to be visualized on a
capillary electrophoresis instrument and yielding
an electropherogram.
The relative height of each probe peak, compared
to the relative peak height in various reference
DNA samples, reflects the relative copy number of
the corresponding target sequence in the sample.
A deletion of one or more target sequences thus
becomes apparent as a relative decrease in peak
height while an increase in relative peak height
reflects amplification. Below figure shows an
electropherogram of a test sample (bottom)
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compared to a reference sample (top), showing a
relative decrease of three probes in the test sample.

Figure 2: Multiplex Ligation-Dependent Probe Amplification

In summary, Duchenne/Becker muscular
dystrophies can be caused by deletions,
duplications, or point mutations in the DMD gene
that encodes the protein dystrophin. However,
to what extent DMD manifests depends on
whether the translational reading frame is lost or
maintained. Partial gene deletions or duplications
in the DMD gene account for as much as ~65% of
cases of these dystrophies. This extremely high
percentage may be due to the nature of the protein
and the gene’s extreme length. The MLPA-based
DMD probe mix contains probes for each of the
exons of the DMD gene (79 exons) on Xp21.2
chromosomes. Performing MLPA reactions is thus
sufficient to investigate the copy number of all
exons. In final assessment, MLPA offers a more
extensive screening than many other methods
used in DMD analysis as it makes it possible to
find deletions/duplications that were previously
overlooked.

TORCH – Why, When, and How?
Dr Ali Raza Nasir, Dr Sobia Khan, Dr Riffat Saleem and
Muhammad Arsalan
Clinical Microbiology

TORCH is an acronym used to refer to infections
that are associated with congenital defects in a
newborn. These infections include toxoplasmosis,
rubella, cytomegalovirus (CMV) and herpes simplex
virus (HSV). Certain literature uses a modified
acronym, TORCHeS, that includes syphilis in
the profile. Knowing which profile, a laboratory
uses as a policy to perform the panel testing for
congenital infections is important for the clinician.
Other congenital infections also associated with
congenital defects include viral hepatitis, HIV,
measles, mumps, parvovirus B19 and varicella zoster
virus, and while these are not a routine part of the
TORCH or TORCHeS profile in most laboratories,
their investigations can be requested separately.
The causative organisms are likely to transmit to a
developing fetus or newborn either trans-placentally,

during passage from the birth canal, or after birth.
There is a variation in the presentation of each of
these infections in the baby, but certain features are
commonly encountered, such as fever, microcephaly,
low birth weight, lethargy, cataracts, hearing loss
and congenital heart disease. Signs and symptoms
may also manifest later in the form of intellectual
disability, deafness, or vision impairment. Early
recognition of these infections in pregnancy is
important in treating the disease, fetal monitoring,
and counselling of the patient regarding adverse fetal
outcomes.
WHY?
Being a developing country, Pakistan faces a
significant burden of adverse pregnancy outcomes.
23
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One of the factors leading to this concerning
situation is the lack of screening for feto-maternal
infections and timely management. In Pakistan,
the incidence of symptomatic CMV infections
in neonates in 2016 was reported to be around
21 percent. For rubella, studies have shown that
a considerable proportion of pregnant women in
rural areas turn out to be positive for IgG and
IgM antibodies (16 percent IgG, 2.5 percent IgM).
Similarly, alarming figures for seroprevalence of
toxoplasma gondii in pregnant women have also
been reported from Pakistan (34.5 percent). This
evidence puts forth a strong argument warranting
the screening of pregnant females for TORCH
infections.
WHEN?
Current practices do not involve routine screening
for TORCH in pregnant females on antenatal
visits. TORCH profiles are usually requested if
there is suspicion on clinical grounds. Certain
guidelines have been published that provide
useful knowledge indicating when to screen for
TORCH infections, such as the ‘TORCH testing
in Obstetrics and Neonatology’ guidelines in
Ireland (Tables 1 and 2) [4]. Abnormal findings on
fetal ultrasound, neonatal clinical abnormalities
and clinical symptoms of the mother such as rash
or hepatitis, warrant the screening of TORCH
infections.
HOW?
The test involves sending a serum sample
to the laboratory where it is tested for the
presence of antibodies against the concerned
pathogens. The serum sample is stable for 48
hours after collection if kept at 2-8oC, and for
6 months if kept at -20oC. A common method
of analyzing the presence of antibodies involves
an enzyme-labeled chemiluminescent sequential
immunometric assay, where antigen coated
beads are made to react with the patient’s serum,
followed by addition of anti-human IgG antibody
bound to an enzyme. A substrate for this enzyme
is added that gets broken down resulting in
generation of light. The presence of antibodies
is determined quantitatively by measuring the
amount of light generated. Slightly different
24
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methods are used for each of the microorganisms
to be tested.
Samples with indeterminate results require retesting.
Similar results on repeat testing require testing by
another method or collecting a second sample after
a reasonable time (e.g., one week). IgM antibodies
are raised when there’s a current or recent infection.
The presence of IgG antibodies in a pregnant woman
usually indicates a past infection or immunity. If there
is a question of an active infection, a second blood
test is performed a few weeks later so the IgG levels
can be compared. If levels increase, it can mean the
infection was recent or is ongoing. Samples that are
hemolyzed, lipemic, icteric, have hyperproteinemia
or hypergammaglobulinemia can interfere with the
results.
New commercially available rapid tests are also
available that qualitatively detect IgG and IgM
antibodies against toxoplasma, rubella, CMV
and herpes simplex one and two. These are
based on an immunochromatographic principle
(much like the malarial ICT) and provide results
within 15 minutes. A positive result by these
methods should be confirmed by alternative
methods.
In conclusion, considering the burden of fetomaternal infections in Pakistan, it becomes
important to educate clinicians regarding when to
screen pregnant women for TORCH, the knowledge
of tests to order and the interpretation of their
results. With the introduction of rapid tests,
clinicians in rural areas can effectively screen
patients preliminarily if they do not have the
facility of established laboratories in the vicinity.
Those that screen positive may be referred to urban
centers for proper evaluation.
KEY POINTS
- TORCH vs TORCHeS: know what your lab offers
- Screen patients for investigation of TORCH based on:

•
•
•

Fetal ultrasound findings
Clinical symptoms of baby
Clinical symptoms of mother

- IgG vs IgM: know how to interpret results; ongoing
infection vs past infection/immunization
- Rapid tests are available, but should be confirmed with
alternative methods
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Tables and Figures:
Table 1: Adapted with modifications from ‘TORCH testing in Obstetrics and Neonatology’ guidelines by Cillian et al
Recommended investigations for the neonate with clinical/laboratory abnormalities at birth
Toxoplasma
Rubella
CMV
Hepatitis/Jaundice/Hepatosplenomegaly
Rash
Thrombocytopenia
Anemia
IUGR
Microcephaly
Hydrocephalus
Failed newborn hearing test
Patent Ductus Arteriosus (at term)
Intracranial calcification
Congenital cataracts or microphthalmia
Hydrops

x

x
x

x
x

x
x
x

x

HSV

x
x
x
x
x
x
x
x

x
x
x

x

Culture negative sepsis not responding to antibiotics in the first
month of life

x

Table 2: Adapted with modifications from ‘TORCH testing in Obstetrics and Neonatology’ guidelines by Cillian et al
Recommended investigations for the pregnant woman with abnormalities detected on fetal ultrasound
Micro/macrocephaly
IUGR
Intracranial calcification
Echogenic bowel
Ventriculomegaly
Structural heart defects

Toxoplasma

Rubella

CMV

x
x
x

x
x
x

x
x
x
x
x

x
x

Figure 1: A commercially available rapid test kit for simultaneous detection of
Toxoplasma, Rubella, CMV and HSV IgG and IgM antibodies. Picture credits: CTK
Biotech
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Twin to Twin Transfusion Syndrome (TTTS)Radiology Approach
Dr. Shayan Anwar
Radiology

Twin to twin transfusion syndrome (TTTS) is one of
the complications that can occur in a monochorionic
monoamniotic or monochorionic diamniotic twin
pregnancy. It can occur in 1:2000 of all pregnancies.
Most striking clinical feature is abdominal distension.
The pathophysiology behind TTTS is imbalanced
supply to both twins because of arteriovenous and
arterioarterial anastomoses in the placental circulation;
one twin receiving more blood supply than the other
(Figure 1).
The imbalance between blood supply leads to reduced
perfusion and blood pressure in one twin (donor) and
increased perfusion and blood pressure in another
twin (recipient). This phenomenon activates the
renin-angiotensin system which subsequently leads to
chronic tubulopathy and oliguria in the hypovolemic
(donor) twin with consequent oligohydramnios,
and polyuria and consequent polyhydramnios in the
hypervolemic (recipient) twin.

Figure 1: Illustration showing the placental anastomotic connection
within a shared placenta that leads to TTTS:
Case courtesy of Dr Matt Skalski, Radiopaedia.org, rID: 68846
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Staging
Staging of this syndrome according to severity is
proposed by Quintero et al. is as given below:
l

oligohydramnios/polyhydramnios

l

bladder not visible in donor twin

l

abnormal Dopplers in either twin

l

hydrops fetalis in either twin*

l

in-utero demise of either twin

stage I:

stage II:

stage III:

stage IV:
stage V:

*Almost always in the recipient; rarely in the donor
if there is coexistent Twin anemia-polycythemia
sequence TAPS.
Radiographic features
On antenatal ultrasound, a) monochorionicity is a
key criterion at any stage of gestation, b) growth
discordance is often but not invariably present and
does not contribute as diagnostic indicator.
First trimester
Increased risk of developing TTTS has been
associated with the following findings on a firsttrimester ultrasound of a monochorionic pregnancy,
although predictive value remains low:
• Nuchal Translucency discordance: 20 percent
or more
• Crown Rump Length discordance: 10 percent
or more
• Ductus venosus reversed a-wave
• Disparity in amniotic fluid volumes (amniotic
fluid discordance) leads to folding of the intertwin membrane as an early sign.
Second and third trimesters
Features that may be noted individually in each twin
include:
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Recipient Twin

Donor Twin

Polyhydramnios (deepest vertical pocket (DVP) >8 cm) (Fig 2)

Oligohydramnios (DVP <2 cm), which may result in the twin
appearing pinned to the side of the gestational sac: "stuck twin"
(Fig 2)

Large or constantly cycling urinary bladder
Features of cardiac overload
Fetal hydrops
Fetal cardiomegaly

Small or non-visualized urinary bladder
Evidence of fetal anemia

In few cases, fetal echocardiography may also show
Atrioventricular valve incompetence
Doppler abnormalities - predominantly venous

Doppler
Umbilical artery Doppler: Absent or reversed diastolic
flow is an indication of worsening twin-to-twin
transfusion syndrome.
Ductus venosus Doppler: Cardiac diastolic dysfunction
is suggested by abnormal waveform pattern.
Treatment and prognosis
Successive sonographic monitoring is standard
practice. Screening for TTTS should start from

Doppler abnormalities - predominantly umbilical artery +/venous

16 weeks’ gestation, in an
uncomplicated monochorionic
twin pregnancy, with
evaluation of fetal growth, deep
vertical pockets (DVPs) and
umbilical arterial pulsatility
index (UA-PI) carried out
fortnightly. Detailed anomaly
scan ultrasound is common
practice at 18-22 weeks.
Additional fetal middle cerebral
arterial-peak systolic velocity
(MCA-PSV) is advocated from
22 weeks onwards.
Up to 90 percent perinatal
mortality is observed in
untreated TTTS with a poor
prognosis. The treatment of
choice is laser coagulation
of the chorionic plate as
it remarkably improves
the prognosis for both
twins. Other treatment
options would include
conservative management
with surveillance for Quintero stage one TTTS and
serial amnioreduction, where laser treatment is not
available.
Differential diagnosis
Oligohydramnios and/or polyhydramnios are
related to fetal structural anomalies.
Isolated placental insufficiency in one of the
twins- will not produce polyhydramnios in
opposite twin.
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Best of the Recent Past
Radiologist #Womenimaging #Followtheirlead
Interview Recorded by Dr Shayan Anwar
Interviewee: Associate Prof Shaista Afzal
1. Please briefly share your initial phase of
journey i.e., from medical graduate to
consultant.
I graduated from Dow Medical College, after
which I completed my internship at Civil
Hospital. I had never thought of becoming a
radiologist. As time passed, I found radiology
to be an emerging field and partook in it as a
challenge. I began my residency in Radiology
at Civil Hospital and after graduation, I started
working at Liaqat National Hospital. Very soon
I got the opportunity to work at AKU where I
joined as an instructor.
2. Considering your entire time as a women
imaging radiologist at your organization, can
you recall a time (any AHAA moment) when
you felt most alive or most excited about your
involvement in the organization?
A distinct time is when our department set up
the section of Women Imaging. Aside from that,
when we get the opportunity to apply the best
possible practices in the field and are able to
train and guide others both at AKU and other
institutions in the country, I feel elated that we are
able to make such a positive contribution.
3. Let’s consider for a moment the things you
value deeply. Specifically, the things you value
about yourself and the nature of your work,
what is the single most important thing your
work has contributed to your life?
Work has added meaningfully to my life. Some
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of the useful qualities
that I have learned
through work are
collegiality, discipline
and perseverance.
4. As a senior women
imaging radiologist
of the country, please
share your experience
of development of women imaging practices in
Pakistan and its future in next 10 years.
There were and are many hurdles particularly
related to the provision of equipment, training of
faculty and staff and awareness in our population.
Women commonly do not come for their breast
screening. When they do the tumors have grown
significantly. We have to increase awareness
among women about their well-being through all
channels such as media and health authorities. In
the years to come, I do see some improvements
but only after we get support from both the public
and private sectors.
5. Any advice for Junior Radiologist?
Over time radiology has been referred to as
clinical imaging. Hence it is important to have
all the information about your patient before you
read any scan or perform any intervention. A
holistic picture of the patient is vital for correct
interpretation and better patient outcomes. I
would also encourage junior radiologists to
actively master the usage of technology and
artificial intelligence as opposed to being hesitant
in using them.
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# Sonography # Followtheirlead
Interview Recorded by Dr Shayan Anwar
Interviewee: Ms. Munawar Jabeen, Senior Charge Radiographer
1. Considering your entire time as charge
radiographer at your organization, can you
recall a time (any AHAA moment) when you
felt most alive or most excited about your
involvement in the organization?
In 2001, when I passed my test and interview for
charge sonographer, that phase was one of the
most exciting ones. I knew the opportunities that
were ahead of me, and I was excited to learn and
grow in my field. Even though throughout my
journey, there have been moments when I felt
the most alive but since this training of charge
sonographer was my first step towards actual
professional growth, I was eager to learn and
explore the world beyond.
2. Please briefly share your initial phase of
journey i.e., from radiographer to charge
radiographer.
The first five years as a radiographer were quite
challenging for me. I completed my intermediate
and bachelors with this job, simultaneously. After
five years of struggles, being a radiographer,
I got promoted to staff radiographer. Then in
2000, I got married and my responsibilities
skyrocketed. It was tough balancing personal and
professional life, but I still managed to keep a
balance between both. From staff radiographer,
I got promoted to senior 1 and after some
time to senior 2. During this time, I became a
mother to two girls, but I ensured my work life
balance does not get disrupted. Being a wife or
a mother never stopped me from getting ahead,
I was always enthusiastic about being a part of
training sessions and attempting to get ahead
in my career. After completing these training
sessions, I became a sonographer and eventually,
charge sonographer. Promotion comes with
added responsibilities, but I always set my work
ethic high. And hence, with my determination
and hard work, I stand on the position of ‘charge
radiographer’ today.

3. Let’s consider for a
moment the things
you value deeply.
Specifically, the
things you value
about yourself and the
nature of your work,
what is the single most
important thing your
work has contributed
to your life?
Accomplishments cannot be bagged without
being honest, showing dedication and striking
a balance in life. My work keeps me proactive,
executing my daily activities with devotion. I
have learnt that your faith might waver but keep
pushing and staying committed is the way to go.
4. As a senior charge radiographer of your
department, please share your experience of
development of Medical Imaging Technology
(MIT) in Pakistan and its future in next 10
years.
I am extremely glad to be a representative
of such an organization that ensures quality
over anything, I have witnessed breakthrough
advancements while working here. When I
first started working in radiology, conventional
methods were employed for radiography which
made the process quite time-consuming. I have
seen the changes from conventional radiography
to computed radiography which is now replaced
by digital radiography. Radiology underwent
several stages of advancements that helped
boost its accuracy and efficiency. With progress
and development in some ground-breaking
technologies, I have experienced some massive
improvements in Radiology. And, in the next 10
years, I believe there will be further developments
in radiology that will continue to evolve.
5. Any advice for Junior Radiographers?
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A few advice I would like to give to junior
radiographers would be to respect your work and
colleagues, both. Respect goes a long way. It’s
simple, give respect and earn respect in return.
Secondly, time management - it is an art of using
your time productively without stressing yourself
out and getting things done before the deadline.
Plan, organize and then implement. You will see a
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huge change. Last and the most important thing is
not to treat your work as a burden. Instead, try to
enjoy it and treat it as a learning experience. Take
constructive criticism in an effective way and
use it as a tool to make positive improvements.
Moreover, always be honest with your work. It
will help you to stay consistent and develop a
sense of trust between your work and colleagues.

#Technologist #Accreditation #CAP
Interview Recorded by Ms. Iffat Arman
Accreditation of clinical laboratories according
to an internationally accepted framework leads to
improvement in quality practices of a laboratory,
generation of accurate test results, reduction in errors
and overall improved efficiency. Accreditations by
College of American Pathologists (CAP) is a very
rigorous practice. The CAP has more than 3500
standards that should be met. The Aga Khan Clinical
Laboratory was accredited by CAP in 2017 and since
then have been reaccredited thrice.

The main stakeholders and the persons doing all the
work to achieve this daunting task are the faculty
and staff of the clinical laboratory. However, the
role each section of our clinical laboratory plays in
clinical care are too many as well as very diverse, so
we requested them to focus on two major areas only.
We interviewed the Quality control coordinators of
the sections to understand challenges faced by each
section in achieving accreditation and how it has
impacted their practices.

Interviewee: Mr. Abdul Mateen, Quality Control Coordinator, Chemical Pathology
Q.1. What were the
challenges you faced while
preparing your section for
the CAP accreditation and
how did you resolve these
challenges?
Talking about the challenges
being faced some of them
were tricky, firstly 2022
was the year for document
revision and with a test
menu of around 250 tests it was a huge task to
achieve. Reviewing every single SOP, equipment
work instruction, sectional policy, QM plan, sectional
patient procedures and numerous other documents
complaining CAP standards and in accordance with
new hospital based templates. Challenging was the
fact that these would go directly for document control
to be reviewed by inspector and responsibility would
be cater by sectional QC coordinator as directed by
Director laboratory CAP.
Q.2. How has CAP accreditation improved your
clinical laboratory practices, quality assurance
and patient safety in your sections?
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Quality control and error detection practices,
document control, practices and procedures of lab
improved, operations became lean and accurate,
results reporting improved, staff efficiency increased,
staff continued educational programs were developed,
competency assessment of staff initiated. Compliance
with the CAP standards lead to overall improvement
of the test result quality and hence patient safety,
raising the standards of care. Nevertheless, it was a
team effort who spend hours and hours of working
to achieve reaccreditation status unaccompanied by
deficiencies.
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Interviewee: Ms. Ayman Jalali, Quality Control Coordinator, Blood Bank
Q.1. What were the
challenges you faced
while preparing your
section for the CAP
accreditation and how
did you resolve these
challenges?
Preparation for CAP
accreditation is
always challenging. Some
of the major issues which we faced are:
• Training and awareness of staff in the mid of
pandemic: Due to Covid, it was very hard for us
to conduct training and awareness sessions as we
had to follow the strict Covid guidelines. Online
sessions were arranged so that maximum number
of participants can be trained at a time.
• Revision of SOPs according to changes in
checklist and its implementation: As revision in
some of the standards demanded changes in
current SOPs, so modifying the work flow
and training the staff according to it was quite
challenging. We conducted some pilot projects
to see which solution suits us as we had to
manage all these changes in current number of
staff and limited space. Although it was very
tough, but with team work and support of our

respectable section heads and physicians, we
made it possible.
Q.2. How has CAP accreditation improved your
clinical laboratory practices, quality assurance
and patient safety.
It has helped us in many ways. In blood bank, the
introduction of Bedside ABO has helped in preventing
wrong transfusions. Also, the introduction of Antibody
screening before red cell transfusion has also
contributed towards patient safety as it ensures safe
transfusion. Quality standards of CAP which include
continuous monitoring of QC and use of only CE/
FDA approved reagents and instruments have let us
improve our overall laboratory practices and quality
assurance.

Interviewee: Ms. Fauzia Naureen, Quality Control Coordinator, Hematology
Q.1. What were the
challenges you faced
while preparing your
section for the CAP
accreditation and how
did you resolve these
challenges?

achieve this task on time as well.
Q.2. How has CAP accreditation improved your
clinical laboratory practices, quality assurance
and patient safety in your sections?

The biggest challenge was
announcement of dates
just few days before the
actual inspection. However, we were able to easily
overcome this concern as CAP standards are now part
of our daily work and extra preparations in this regard
were not required. Our trust in each other as a team
further boosted our confidence. Review of revised
SOPs and Policies had to be done in very short time
frame but our cooperation amongst us helped us
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CAP accreditation has brought remarkable
improvement in our section. Our knowledge of
quality assurance and staff practices regarding
maintaining quality assurance have improved
significantly. They now better understand the
significance of fulfilling all desired QC steps.
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Implementation of advanced QC tools such as delta
check, moving averages, validation of tests before
implementation and participation in proficiency
testing surveys on unknown samples are few
examples that has contributed to culture of ensuring
patient safety.

Interviewee: Ms. Samina Ghani, Quality Control Coordinator, Molecular Pathology
Q.1. What were the
challenges you faced
while preparing your
section for the CAP
accreditation and how
did you resolve these
challenges?
Molecular pathology is
one of the most diverse
section of clinical
laboratory and its continuing evolving with new and
recent technologies in research and diagnosis. This
time Covid 19 is a great challenge for our laboratory
and initially its very tough to maintain high
volumes of covid 19 in limited resources with
CAP parameters. But later on with support and
encouragement of our management we introduced
High Throughput automated testing and by the
continuous struggle and hard work of our team we
achieve the goal.

Q.2. How has
CAP accreditation
improved your
clinical laboratory
practices, quality
assurance and
patient safety in
your sections?
CAP standards are
very effective for
highly complex
molecular testing along with Quality assurance.
It has great impact on validation of new tests.
It improves testing efficiency, customer service and
reduce rates of laboratory errors. CAP accreditation
also improve our patient care by aiding the timeliness
and accuracy of medical decision. our section
also Participation in Proficiency testing(PT) which
is a key component of accreditation, leads to more
accurate test results.

Charge Technologist #Accreditation #CAP
Interviewee: Ms. Najma Shaheen, Quality Control Coordinator, Microbiology
Q1. What were the
challenges you faced while
preparing your section
for the CAP accreditation
and how did you resolve
these challenges?
Due to the pandemic
scenario this audit was
conducted after gap of
4 years. The major challenge was the scarcity of
human workforce to continue the routine laboratory
operations but also handling CAP related issues
and preparation. To limit the COVID exposure, we
had not only implemented the hospital policy very
vigilantly but also restrict our laboratory staff.
Initially we were unable to do onsite meetings
because of COVID related restrictions; however, when
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things look black, there’s always a silver lining. We
started to use online meeting tools i.e., ZOOM and
MS team and everyone get skilled with these methods
within short span of time.
Q.2. How has CAP accreditation improved your
clinical laboratory practices, quality assurance
and patient safety in your sections?
1. We have updated our laboratory processes
and diagnostic technology in view of CAP
standards and regular proficiency testing.
2. Quality projects is an important tool that has
helped us to identify on our gaps and get the
solutions with better outcome for patients.
3. Our staff is now trained for laboratory
diagnosis and safety according to the
international recommendations and guidelines.
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Interviewee: Ms. Somiayya Sohail, Quality Control Coordinator, Histopathology
Q1. What were the
challenges you faced while
preparing your section for
the CAP accreditation and
how did you resolve these
challenges?

hours. Another tedious task was to formulate a
policy for the new standard that had been recently
introduced by CAP. This was related to the fixation
time of tissue. Since it was a new edition, we had to
ensure that this policy was followed by consultants
across the board.

Preparing for the CAP
inspection was a laborious
task, but at the same time
offered great learning
experience. We had to cover
almost 300 standards mentioned in the checklist,
that has been provided by the College of American
pathologists. These standards are pertinent to
the areas of Anatomic pathology, Cytology,
flowcytometry and semen analysis. Since there is
heavy service load in our lab, accomplishment of
this task has been challenging. A few exceptionally
demanding tasks encountered during preparation
included daily updating of equipment binders. Since
service took most of our time during the morning
hours, this part was done during the night duty

Q.2. How has CAP accreditation improved your
clinical laboratory practices, quality assurance
and patient safety in your sections?
Implementing the CAP standards strictly reduces
the chances of errors and improves accuracy of tests.
This is related to the stringent quality assurance
measures as laid down by CAP.
In short, accreditation establishes safe practices
that are necessary for accurate, reliable, and timely
reporting of specimens. These measures are not
only beneficial from the patient perspective, but
also provide a safe working environment for the
laboratory personnel.

HAPPENINGS IN PATHOLOGY
CAP Accreditation Journey- Excellence in
Total Quality Management
Dr Sibtain Ahmed
Clinical Chemistry

From healthcare perspective, accreditation is defined
as a robust process involving an official review of an
organization to ensure that it meets official regulatory
requirements and standards. College of American
Pathologists (CAP), laboratory accreditation program
was initiated in 1961. This accreditation is regarded
as the epitome of laboratory excellence in total
quality management. The process entails a continuous
quality improvement journey subjected to a stringent
review of the entire operations by an external team
of laboratory professionals (trained CAP auditors)
using more than 3000 standards. Compared to
other standards and quality management programs
CAP accreditation holds a distinct edge, based
on the detailed set of factors and areas it inspects

focused upon performance of clinical laboratories.
The standards are broad-based statements that
specify the requirements for the director of the
laboratory, physical facilities and safety, quality
management, administrative requirements of the
program, performance improvement, and inspection.
In a nutshell, CAP accreditation ensures that the
laboratories demonstrate continuous steps to identify
and correct deficient areas and improve performance,
in compliance with the Clinical Laboratory
Improvement Amendments of 1988 regulatory
requirements.
AKUH Clinical Laboratories is the largest
laboratory network in Pakistan. Housing the hub at
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the main clinical laboratory in Karachi, the network
comprises of more than 291 collection units and 13
regional stat laboratories, across the country. With
a highly trained team of professionals, and stateof-the-art automated equipment, the laboratories
offer over 500 different types of testing mounting to
approximately 10 million tests annually. The AKUH
clinical laboratory achieved CAP accreditation in
2016, then successfully passed the biennial review
in 2018. In the wake of COVID-19, the subsequent
re-accreditation audit took place from 10-11th
March 2022. In this comprehensive audit a team of
eight international CAP trained auditors physically
inspected the facility. The two days inspection
involved a thorough and stringent review of Clinical
Chemistry, Haematology & Transfusion medicine,
Microbiology, Molecular Pathology, HLA and
Cytogenetics, Immunology, Point of care testing,
Coagulation and Flow Cytometry, Histopathology
and Cytopathology, laboratory general and safety.
Subsequently, on 2nd June 2022, we received our
3rd CAP re-acreditation with ZERO deficiency for
the main lab Karachi, which is a testament of the
highest standards of total quality management. The
CAP inspection team leader quoted that “AKU lab
is one of the best labs in the region and are well
on their way to become one of the best labs in the
world”. Collection of glimpses from the recent audit
is presented here:

Audit of Clinical Chemistry

Team POCT with CAP auditor

Microbiology faculty with auditor during inspection
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Histopathology faculty with the auditor
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Metabolomics Book Club-A New Teaching
Learning Strategy in Chemical Pathology
Dr Arsala Jameel Farooqui and Dr Lena Jafri
Chemical Pathology

Developments in the techniques of analytical
clinical chemistry and metabolomics are the
source of the rapid evolution of a new omics era.
The introduction of metabolomics in the Section
of Chemical Pathology at Aga Khan University,
Karachi Pakistan pertains to important platforms:
analytical techniques like GCMS, FTIR, HPLC
and LCMSMS. With the introduction of mass
spectrometers and HPLC in the section almost
eight-nine years ago metabolic profiling of patients
suspected of having inherited metabolic disorders

of understanding by the end of the one-hour long
monthly session.

can be done. We have screened > 22000 high risk
children and adults in past eight years and have
identified around 40 disorders using these cuttingedge technologies. The Biochemical Genetics
Laboratory in the section has established some
targeted metabolomics panels for quantitation
of selected groups of metabolites using mass
spectrometry specifically for inherited metabolic
disorders and new-born screening (LCMSMS).
To facilitate understanding of metabolomics and
to enhance the science of metabolomics a monthly
activity of ‘Metabolomics Book Club’ was initiated
in the section of Chemical Pathology, Department
of Pathology and Laboratory Medicine at Aga
Khan University. The goal was that the participants
facilitate the discussion and are at the same level

was read aloud in circle and discussed in depth.
There were nearly nine to ten people in the
room, including faculty, residents, technologists,
and research associates. Discussion on various
techniques and methods of metabolomics and their
sensitivities and specificities was done. The group
identified potential research areas on metabolomics
between readings.

In the beginning the activity director introduced
the structure of the book club and the cover of the
book. The participants were seated in a small room
and read a pre-selected book on metabolomics in
a circle. New knowledge gained was discussed
between readings. The first chapter “Introduction to
Metabolomics” of the book titled “Metabolomics:
From Fundamentals to Clinical Applications”

The second session emulated the energy of the
initial session, the readers engaged in perusing the
second chapter of the same book: Collection and
Preparation of Clinical Samples for Metabolomics.
Eight to ten readers indulged in an hour-long
discussion on the fundamentals of metabolomics
related to non-specific samples received in the
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clinical laboratory. Types of samples and testing
techniques were discussed by the consultants,
residents, and biogenetics lab scientists in
attendance, who took turns to read aloud the pages
and actively discussed the important aspects of
metabolomics related to sampling in real-time.

made predictions, and clarified difficult and new
concepts of metabolomics. Novel information of
metabolomics was disseminated to all on the same
level. All participants enjoyed this novel approach
of teaching and besides discussion on science it
promoted a love for books and a positive attitude
towards reading.
The metabolomics book club has allowed
participants to have a deeper understanding of the
book and metabolomics’ application to service,
education and research.

At the end of each session the group of readers
summarized reading, shared their experiences,

Polaroid

Laboratory team member processing Amniotic fluid samples for fetal cell culture in tissue culture flasks. In the Section
of Molecular Pathology Karyotyping, FISH aneuvysion, Thalassemia, DMD and SMA tests are performed in an
amniotic fluid specimen.
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Polaroid

Molecular pathology team members involved in Feto-Maternal Diagnostics testing. Feta Maternal Diagnostic tests
performed at the Section of Molecular Pathology include Karyotyping, FISH aneuvysion, Thalassemia, DMD and SMA.

A senior technologist at the Section of molecular Pathology preparing patient’s sample for molecular analysis of Alpha
Thalassemia by MLPA technique.
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Polaroid

Visualization of Amniotic fluid slides prepared using Fluorescence in situ hybridization (FISH) technique for Trisomy 18.

Figure: Beta Hemolytic colonies of Group B Streptococcus
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Polaroid

Performance of automated red cell antibody screening & identification in Hematology Lab.

Technologist performing renal stone analysis of a pediatric renal stone using Fourier Transform Infrared Spectroscopy.
The most common component reported in pediatric age group is ammonium hydrate.
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Polaroid

Technologists performing Kleihauer Betke test for evaluation of feto-maternal hemorrhage

Pathologist reporting the triple test results for evaluation of Down syndrome and neural tube defects.
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Polaroid

Technologist performing the Thyroid Receptor antibodies (TRAb) using Electrochemiluminescence Immunoassay
methodology on the Cobas e411 analyzer (Roche Diagnostics, US)

Gynecology tumor board group. Left to right: Dr. Taha Nafees (PGY-I), Dr. Rabia Qureshi (PGY-III), Dr. Naila Kayani
and Dr. Romana Idress
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The Tests for Congenital Endocrine and
Inherited Metabolic Disorders
Dr Nawazish Zehra, Dr Hafsa Majid
Clinical Chemistry

Name

Indication

Sample Type

DBS Acylcarnitine
and Amino Acids

Screening for inherited
Dry Blood
metabolic disorders
Spot (Filter
(Organic Acidemias,
paper)
Aminoacidopathies, Urea
cycle disorders, Fatty acid
oxidation defects)

Patient Prerequisite

Reporting Schedule

Interpretation

Sample collected from Performed on 2nd
heel prick from 0-30
and 4th Thursday of
days of birth
month and report on
following Wednesday

Interpretation based
on quantity and
pattern recognition

Neonatal biotinides Early detection of curable Dry Blood
deficiency (NBTD) congenital diseases as a
Spot (Filter
part of NBS
paper)

Sample collected from Performed on 2nd
heel prick from 0-30
Wednesday of
days of birth
month and report on
following Friday

BTD is termed as
screen positive if
levels are <60nmol/
min/dl

17-Hydroxy
Progesterone
(17OHP)

Newborn Screening
for Congenital Adrenal
Hyperplasia

Dry Blood
Spot (Filter
paper)

Interprétation base
on gestational age
and birth weight
based cutoffs

Neonatal Thyroid
Stimulating
Hormone (NTSH)

Newborn Screening
for Congenital
Hypothyroidism

Dry Blood
Spot (Filter
paper)

Sample collected from Performed on every
heel prick after 24-72 Tuesday and Friday
and reported on the
hours of birth
following Thursday
and Monday
Sample collected from Performed daily from
heel prick after 24
Monday to Saturday
hours of birth (ideally and reported after 2
48-72 hours of birth) working days

Urine Organic Acid Diagnose inherited
Urine Sample
(UOA)
metabolic disorders
(Organic Acidemias,
Aminoacidopathies, Urea
cycle disorders etc.)

Random urine sample
without preservative
(preferably early
Morning sample)

Performed daily from
Monday to Friday
Reporting after 10
working days of
sample collection

Interpretation
based on pattern
recognition

Plasma Amino Acid Diagnose inherited
Plasma sample
(PAA)
metabolic disorders
(EDTA tube)
(Organic Acidemias,
Aminoacidopathies, Urea
cycle disorders etc.)

Fasting at least 2
hours in infants, 4
hours in children and
8 hours in adults.

Performed daily from
Monday to Friday
and reported after
13 working days of
sample collection

Interpretation based
on quantity and
pattern recognition

Succinyl Acetone

Diagnose Tyrosinemia
Type 1

Urine

Early Morning
random urine sample
without preservative

Performed on every
Wednesday and
reported on the
following Wednesday

Interpretation
based on quantity
of succinylacetone
(SUAC)

Maple syrup urine
disease (MSUD
Profile)

Diagnose and monitor
patients with MSUD

Plasma Sample Fasting at least 2
(Lithium
hours in infants, 4
Heparin Tube) hours in children and
8 hours in adults

Performed on every
Monday and reported
on the following
Wednesday

Quantitative results
for the branched
chain amino acids

Homocysteine
Profile

Diagnose and monitor the Plasma Sample Fasting at least 2
homocystinuria
(Lithium
hours in infants, 4
(cystathionine β-synthase Heparin Tube) hours in children and
deficiency,
8 hours in adults
methylenetetrahydrofolate
reductase deficiency and
intracellular cobalamin
defects etc.)

Performed once in a
week (Tuesday)

Quantitative
results for the
Homocysteine and
methionine

Methyl malonic acid To diagnose and monitor
(MMA)
patients with Vitamin
B12 Deficiency and
Methylmalonic Aciduria
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Plasma Sample Random sample
(Lithium
Heparin)

Reporting same day

Performed on 1st
and 3rd Monday
and reported on the
following Wednesday

Screen Positive
if levels are
>10mIU/L

Quantitative results
for the MMA
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Orotic Acid

Diagnose Urea cycle
disorders

Urine sample

2 to 5 ml of spot or
Performed on Thursday Quantitative results
Random Urine Sample and reported on Monday for the Orotic Acid

Sugar
chromatography

Detects Sugars (glucose,
Fructose, lactose,
galactose, sucrose,
xylose) using thin layer
chromatography

Urine

Random urine sample. Perform every
Tuesday and report
on the following
Thursday

Presence/absence of
different reducing
sugars

New Tests in Clinical Laboratory
Renal Indices

The Section of Chemical Pathology,
Department of Pathology & Laboratory
Medicine, is pleased to announce the
introduction of six new tests/ biochemical
indices. Decisions based on these biochemical

indices using several urinary and serum
markers may provide aid in the evaluation
of electrolyte disorders, tubular function,
metabolic bone disorders and differentiating
between prerenal, renal and post-renal
etiologies. These tests will support clinical
decision making in many specialties.

S#

Test Description & Mnemonic

Sample
requirement

Reporting Turnaround
Time

Clinical Utility

1

Fractional Excretion of
Potassium, FEK

Random urine
and 3-5 cc blood
sample

Monday to Saturday,
reporting next day

Is useful for determining the cause for hyperor hypokalemia. Renal losses of K+ may
occur during the diuretic (recovery) phase of
acute tubular necrosis, during administration
of non-potassium sparing diuretic therapy,
and during states of excess mineralocorticoid
or glucocorticoid

2

Trans-Tubular Potassium
Gradient, TTKG

Random urine
and 3-5 cc blood
sample

Monday to Saturday,
reporting next day

It is an index reflecting the conservation of
potassium in the cortical collecting ducts of
the kidneys. It is useful in diagnosing the
causes of hyperkaliemia or hypokalemia

3

Urine Anion Gap, UAG

Random urine
sample

Monday to Saturday,
reporting next day

It represents an indirect index of urinary
ammonium excretion in patients with
hyperchloremic metabolic acidosis

4

Spot Urine Calcium to
Creatinine Ratio, SUCCR

Random urine
sample

Monday to Saturday,
reporting next day

It is used to screen for hypercalciuria.
Increased urinary excretion of calcium
accompanies hyperparathyroidism,
vitamin D intoxication, metastasis from
prostatic cancer, and following calcium
supplementation

5

Tubular Phosphate
Reabsorption to the
Glomerular Filtration Rate,
TmP/GFR

Random urine
and 3-5 cc blood
sample

Monday to Saturday,
reporting next day

Is used to evaluate renal phosphate transport.
It is useful in assessing renal reabsorption
of phosphate in a variety of pathological
conditions associated with hypophosphatemia

6

Fractional Excretion of
Calcium, FECA

24hrs urine &
3-5 cc blood
sample

Monday to Saturday,
reporting next day

Widely used as a measure for differentiating
patients with familial hypercalcemic
hypocalciuria from those with Primary
hyperparathyroidism
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